Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
Price : $35 *
At a glance
- Drugs Mizoribine (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms AMOLED
- Sponsors Chong Kun Dang
- 25 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov.
- 25 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 25 Jun 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.